Table 3. Summary of adverse events.
| Event |
Total (n=76) |
High-dose VitC (n=46) |
Standard therapy (n=30) |
| Any adverse event | 37 (48.7) | 19 (41.3) | 18 (60.0) |
| Lymphopenia | 7 (9.2) | 3 (6.5) | 4 (13.3) |
| Leukopenia | 1 (1.3) | 1 (2.2) | 0 |
| Thrombocytopenia | 8 (10.5) | 4 (8.7) | 4 (13.3) |
| Increased aspartate aminotransferase activity | 5 (6.6) | 3 (6.5) | 2 (6.7) |
| Increased alanine aminotransferase activity | 3 (3.9) | 2 (4.3) | 1 (3.3) |
| Increased total bilirubin level | 15 (19.7) | 6 (13.0) | 9 (30.0) |
| Increased serum creatinine level | 6 (7.9) | 3 (6.5) | 3 (10.0) |
| Increased creatine kinase isoenzyme-MB activity | 2 (2.6) | 1 (2.2) | 1 (3.3) |
| Increased high sensitivity-cardiac troponin I level | 5 (6.6) | 3 (6.5) | 2 (6.7) |
| Increased N-terminal pro-B-type natriuretic peptide level | 5 (6.6) | 3 (6.5) | 2 (6.7) |
| Serious adverse event | 6 (7.9) | 1 (2.2) | 5 (16.7) |
| Respiratory failure or ARDS | 5 (6.6) | 1 (2.2) | 4 (13.3) |
| Shock | 2 (2.6) | 1 (2.2) | 1 (3.3) |
| Sepsis | 2 (2.6) | 1 (2.2) | 1 (3.3) |
Data are n (%). Adverse events that occurred in more than 1 patient through follow-up. Some patients had more than one adverse event. All deaths were caused by respiratory failure. ARDS: acute respiratory distress syndrome; VitC: vitamin C.